topotecan has been researched along with olaparib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Borst, P; de Water, N; Gunnarsdottir, S; Jaspers, JE; Jonkers, J; Kersbergen, A; Nygren, AO; Pajic, M; Rottenberg, S; van der Burg, E; van Tellingen, O; Zander, SA | 1 |
| Carmichael, J; Cassidy, J; Macpherson, E; Ranson, M; Samol, J; Scott, E; Thomas, A | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M | 1 |
| Adams, DJ; Balmus, G; Barros, AC; Beli, P; Bradley, A; Chen, E; Coates, J; Demir, M; Durant, ST; Forment, JV; Fu, B; Galanty, Y; Herzog, M; Jackson, SP; Martinez, FM; Metzakopian, E; Ostermaier, M; Pilger, D; Ponstingl, H; Sczaniecka-Clift, M; Stankovic, T; Woods, M; Yang, F; Yusa, K | 1 |
1 review(s) available for topotecan and olaparib
| Article | Year |
|---|---|
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
1 trial(s) available for topotecan and olaparib
| Article | Year |
|---|---|
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Demography; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2012 |
4 other study(ies) available for topotecan and olaparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, p53; Mammary Neoplasms, Animal; Maximum Tolerated Dose; Mice; Mice, Knockout; Phthalazines; Piperazines; Topoisomerase I Inhibitors; Topotecan | 2010 |
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea | 2016 |
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; Cell Line, Tumor; Cell Survival; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Ligase ATP; DNA Replication; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred NOD; Mice, Knockout; Mouse Embryonic Stem Cells; Mutation; Neoplasms, Experimental; Phthalazines; Piperazines; Topotecan | 2019 |